In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...
Broad endorsement for insurance-covered blood-based CRC screening (92%) suggests payer policy could materially influence uptake among guideline-eligible, average-risk adults starting at age 45.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results